We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| AGI | AGI | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 7.25 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 7.25 | 7.25 |
| Top Posts |
|---|
Posted at 09/1/2012 18:08 by g_s I only bought here in November so was delighted to sell today with a good profit. I would say that longer term investors probably deserved a slightly higher premium due to the cash the company has and the value of any IP. I wish you guys who continue to hold all the best with your investment, and fingers crossed you can squeeze a couple more pence out of the deal.GS |
Posted at 09/1/2012 07:03 by topinfo Offer for AGI Therapeutics plcAlert TIDMAGI RNS Number : 1836V AGI Therapeutics plc 09 January 2012 For immediate release Not for release, publication or distribution, in whole or in part, in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction 09 January 2012 PRE-CONDITIONAL RECOMMENDED CASH OFFER BY ARAVIS THERAPEUTICS LIMITED FOR AGI THERAPEUTICS PLC Summary -- The boards of Aravis Therapeutics Limited ("Aravis") and AGI Therapeutics plc ("AGI") are pleased to announce that they have reached agreement on the terms of a recommended cash offer by Aravis for the entire issued and to be issued share capital of AGI. -- AGI is a specialty pharmaceutical company which is focused on the development and commercialisation of differentiated specialty drug products to treat un-met medical needs, including conditions which qualify for orphan drug status. -- Under the terms of the Offer, AGI Shareholders will be entitled to receive US$0.1171 in cash for each AGI Share they own. -- AGI Shareholders will be able to elect to receive their entire cash consideration pursuant to the Offer either in US Dollars or Euro. The Euro cash amount payable will be determined based on the prevailing US$/EUR exchange rate either on the day the Offer becomes or is declared wholly unconditional or if valid acceptances are received after that date then on the day their cash consideration is converted into Euro. -- The Offer values the entire issued and to be issued share capital of AGI at approximately US$8.4 million (EUR6.6 million). -- Based on the closing US$/EUR exchange rate of 1.2776 on 06 January 2012, being the latest practicable date prior to the date of this announcement, the Offer values each AGI Share at EUR0.0917. This represents: -- a premium of approximately 67 per cent. to the Closing Price of EUR0.055 per AGI Share on 06 January 2012, being the last Business Day prior to the date of this announcement; -- a premium of approximately 130 per cent. to the average daily Closing Price per AGI Share for the three months up to the last Business Day prior to the date of this announcement, being EUR0.040; -- a premium of approximately 137 per cent. to the average daily Closing Price per AGI Share for the six months up to the last Business Day prior to the date of this announcement, being EUR0.039. -- The making of the Offer is conditional upon satisfaction of the pre-condition set out in Appendix III to this announcement. The pre-condition requires Aravis to receive by 12 noon on the date of this announcement irrevocable undertakings in a form satisfactory to Aravis from AGI Directors, and the AGI Investors to accept (or procure the acceptance of) the Offer in respect of 31,359,118 AGI Shares and, to the extent exercised, 4,200,000 "in the money" AGI Share Options, in aggregate representing approximately 49.6 per cent. of the entire issued and to be issued share capital of AGI at the date of this announcement. -- The Board of AGI, which has been so advised by Davy Corporate Finance, considers the terms of the Offer to be fair and reasonable. In providing its advice, Davy has taken into account the commercial assessments of the Board of AGI. -- Accordingly, the Board of AGI unanimously recommends that AGI Shareholders accept the Offer. Commenting on the Offer, Ronan Lambe, Non-Executive Chairman of AGI, said: "AGI is pleased to announce the Offer, which has been unanimously recommended by our Board of Directors. We believe the Offer represents an attractive premium relative to our recent share price trading history and when the Offer is considered alongside other alternatives the Offer represents the best outcome for Shareholders". This summary should be read in conjunction with the full text of the following announcement and appendices. The Offer will be subject to the conditions and further terms set out in Appendix I of this announcement, which will also be set out in the Offer Document and the Form of Acceptance. Appendix II contains the bases of calculation and sources of certain information contained in this announcement. Appendix III sets out the pre-condition to the making of the Offer. Appendix IV sets out definitions of certain terms used in this announcement (including in this summary). Davy Corporate Finance is acting as financial adviser to AGI. Beauchamps Solicitors are acting as legal adviser to AGI. Goodbody Corporate Finance is acting as financial adviser to the Aravis Group. A&L Goodbody is acting as Irish legal adviser and Burke, Warren, MacKay & Serritella, P.C is acting as US legal adviser to the Aravis Group. Enquiries: |
Posted at 28/10/2011 12:31 by nils214 what does AGI350 target apart from 'unmet medical needs' - seems to me that AGI don't even inform investors what products they are developing? On their website their only product is agi350? No info on how much cash they expect to use to take it to a successful launch and what would be the projected returns? Even with the cash in the bank, and with only 1 product, seems a v. high risk play?? |
Posted at 07/10/2011 10:02 by fairdeal2008 chrisis33I have no idea how agi-350 will turn out, although all looks positive thus far from rns. But my point is its low cash burn and £6mn in the back or approx 9p with only 67million shares in issue. If just a few investors got behind the share and were buying the impact would be very material and would correct imho this undervaluation... But there you are... People will clammer for stock like crazed fools when the share price is 18,19,20p... but when 3.5p ooohhh caution is required...eh? imho please dyor |
Posted at 14/8/2011 13:33 by topinfo Sooner or late Private Equity firms are going to be snapping up these companies that are valued at a significant discount to cash, its inevitable. Even though the mkt for some reason discounts them to their cash there arent many companies out there that have more cash than mkt cap, and by more we are talking 50-200% more for some.SEA is 55% discount to cash and assets for free. AGI is 200% discount to cash and assets/products for free. So why dont we make some real money. If we can think of it, Im sure there are others doing the sums right now and could make instant profits from just buying out these firms and stripping the cash out of them. So for instance, seen as most of us cant afford to buy them alone. We get 10 investors to form a takeover group and buy AGI for 6p per share for entire issued share capital, thats 100% premium to current share price We will have already started snapping up shares at these levels. We make £2.2 million from returning cash to shareholders and we also make on the premium on the share price from where we bought in. Thats £220k each plus whatever was put up to aquire the cheap shares too. Easy eh. And the same can be said for SEA etc, but of course you are talking alot more money in the first place to stump up. |
Posted at 25/5/2011 09:30 by christianf12 Might as well grab the first post box : )AGI is completely off the radar of most investors as if you take a look how many posts have been put on the previous thread it is only 460 in 5 years!!! And only 67 posts on the previous one. |
Posted at 27/4/2011 09:44 by fairdeal2008 Don't be silly stamply2.I invest on propositions I like and if a company ever gave out anything remotely price sensitive imho I would run a mile. Management should never reveal anything sensitive to an individual investor. What I want to see when I contact a company is an open approach and willingness to communicate with investors. That is all. The rest you have to get from your research and imagination. I envisage this at 25p plus soon - then the nmkt cap will be less than assets by some margin and I will have a 5x increase. Most people will not be brave or stupid enough to buy now. But that is how I make my money - by buying before others have the stomach too... imho |
Posted at 29/3/2011 09:54 by moreforus FD last 5 trading days of the tax year will drive investors to take tax rather than investment lead decisions...can buy at full ask at tdw in small 100k is 5.2p |
Posted at 12/4/2007 14:48 by lbo AGI Therapeutics Shares: 127½p unchanged Questor says Buy Executives in the drugs sector are not known for their parsimony. Despite the fact that most do not make profits, the bosses of many British biotech and pharmaceuticals companies like to spend their companies' money as if it magically grew on trees. Not so AGI Therapeutics, which operates out of serviced offices in Dublin. With a market capitalisation of £86m, the company is not a minnow in its sector, yet it employs just eight people. Most of its work - ranging from carrying out clinical trials to analysing the data - is outsourced. AGI's business model is also devoid of airs and graces. AGI, run by chief executive John Devane, and finance director David Kelly, both veterans of Ireland's Elan, takes established drugs and finds new uses for them. AGI has five drugs in its pipeline. Because its products have been tested in other contexts, the length of trials and costs are lower than for new chemical entities. It has taken just two years for AGI to develop its irritable bowel syndrome (IBS) product from early trials to the verge of phase three, a milestone it announced yesterday. AGI aims first to target specialist doctors dealing with IBS in the US and then to roll it out to general practitioners - a formula which has been used before successfully by small drugs companies with limited budgets. It will not employ a salesforce until it is much further down the line. Not all investors are convinced by the model of reformulating existing drugs. Yet AGI's risk profile is lower than that of many small biotech and pharma companies because it is not dealing with the unknown. AGI yesterday said its annual loss narrowed from \u20AC5.2m (£3.5m) to \u20AC4.2m. It has enough cash to last for the next two years. One to watch |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
